FDA Tells 23andMe To Halt Gene Tests - InformationWeek

InformationWeek is part of the Informa Tech Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them.Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

IoT
IoT
Comments
FDA Tells 23andMe To Halt Gene Tests
Oldest First  |  Newest First  |  Threaded View
Thomas Claburn
50%
50%
Thomas Claburn,
User Rank: Author
11/25/2013 | 4:47:19 PM
The problem with errors
This recent blog post suggests why 23andMe data might be problematic.
Alex Kane Rudansky
50%
50%
Alex Kane Rudansky,
User Rank: Author
11/25/2013 | 5:41:56 PM
Re: Unnecessary Worry and Expense
I agree that wrong information is worse than no information. I've spoken with people who believe personalized healthcare, stemming from genomics, will be the next wave in healthcare. I wonder when we'll start to see FDA-approved versions of this.
David F. Carr
50%
50%
David F. Carr,
User Rank: Author
11/25/2013 | 10:49:57 PM
Game over?
Is this game over for 23andme? Does the FDA give them any out, any way to redeem themselves?

Sounds like no genetic tests = no businesses for them

Thomas Claburn
50%
50%
Thomas Claburn,
User Rank: Author
11/26/2013 | 12:34:22 PM
Re: You get what you pay for
I suspect the issue is the company can't sell $99 tests that have also been conducted with sufficient regulatory rigor. And $999 tests just won't sell well enough without a very clear benefit to consumers.
David F. Carr
50%
50%
David F. Carr,
User Rank: Author
11/27/2013 | 4:36:33 PM
23andMe replies to FDA
The company is not giving up without a fight.

This was posted to the company blog and signed by CEO Anne Wojcicki:

23andMe was started in 2007 with the belief that consumers have the right to get access to their genetic information and that information can help them live healthier lives.

It is absolutely critical that our consumers get high quality genetic data that they can trust.   We have worked extensively with our lab partner to make sure that the results we return are accurate.  We stand behind the data that we return to customers — but we recognize that the FDA needs to be convinced of the quality of our data as well.

In 2008 we began our dialogue with the FDA. The relationship with the FDA remains critically important to 23andMe.

In July 2012 23andMe submitted its first application for FDA clearance and followed on with another submission at the end of August. We received feedback on those submissions and acknowledge that we are behind schedule with our responses.

This is new territory for both 23andMe and the FDA. This makes the regulatory process with the FDA important because the work we are doing with the agency will help lay the groundwork for what other companies in this new industry do in the future. It will also provide important reassurance to the public that the process and science behind the service meet the rigorous standards required by those entrusted with the public's safety.

I am committed to making sure that 23andMe is a trusted consumer product. I believe that genetic information can lead to healthier lives — a goal that all of us share.

We will provide updates as they become available.

Accordint to Techcrunch, Wojcicki also sent out a letter to customers, saying:

We stand behind the data that we return to customers – but we recognize that the FDA needs to be convinced of the quality of our data as well.

23andMe has been working with the FDA to navigate the correct regulatory path for direct-to-consumer genetic tests. This is new territory, not just for 23andMe, but for the FDA as well. The FDA is an important partner for 23andMe and we will be working hard to move forward with them.

 







2021 State of ITOps and SecOps Report
2021 State of ITOps and SecOps Report
This new report from InformationWeek explores what we've learned over the past year, critical trends around ITOps and SecOps, and where leaders are focusing their time and efforts to support a growing digital economy. Download it today!
InformationWeek Is Getting an Upgrade!

Find out more about our plans to improve the look, functionality, and performance of the InformationWeek site in the coming months.

Slideshows
10 Things Your Artificial Intelligence Initiative Needs to Succeed
Lisa Morgan, Freelance Writer,  4/20/2021
News
Tech Spending Climbs as Digital Business Initiatives Grow
Jessica Davis, Senior Editor, Enterprise Apps,  4/22/2021
Commentary
Optimizing the CIO and CFO Relationship
Mary E. Shacklett, Mary E. Shacklett,  4/13/2021
Register for InformationWeek Newsletters
Video
Current Issue
Planning Your Digital Transformation Roadmap
Download this report to learn about the latest technologies and best practices or ensuring a successful transition from outdated business transformation tactics.
White Papers
Slideshows
Twitter Feed
Sponsored Live Streaming Video
Everything You've Been Told About Mobility Is Wrong
Attend this video symposium with Sean Wisdom, Global Director of Mobility Solutions, and learn about how you can harness powerful new products to mobilize your business potential.
Sponsored Video
Flash Poll